Argos Therapeutics Director of Immunology to Present at HIV

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Argos Therapeutics Director of Immunology to Present at HIV Vaccines Meeting

DURHAM, N.C., March 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq: ARGS ) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today announced Dr. Mark DeBenedette, the company's director of immunology, will present at the HIV Vaccines meeting, part of the Keystone Symposia Global Health Series. The meeting will be held March 22-27 th at the Fairmont Banff Springs in Alberta, Canada.

During Poster Session 1 on March 23 rd , Dr. DeBenedette will review immunologic outcomes from a double blind placebo controlled Phase IIb clinical trial of AGS-004, the company's investigational immunotherapy for the treatment of HIV. The study evaluated the ability of AGS-004 to induce HIV specific T-cell immunity prior to and during interruption of antiretroviral therapy.

The poster is titled, "AGS-004, an Autologous Dendritic Cell Therapy, Induces Multi-Functional CTL Responses in Chronically Infected HIV Subjects."

About the Arcelis® Technology Platform

Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease specific antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com .

Forward Looking Statements

Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent Argos' views as of March 20, 2015. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to March 20, 2015.

Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 Investor contact: Nancy Yu Burns McClellan 212-213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading

Top 5 Most Recently Viewed Articles

FHLBank San Francisco's $10M Investment in Housing Solutions

Updated Category News Views 188

FHLBank San Francisco's Strategic Commitment to Affordable Housing In a significant move to address housing affordability, the Federal Home Loan Bank of San Francisco (FHLBank San Francisco) has made a $10 million investment in a bond issuance backed by Freddie Mac. This vital investment is set to maintain the affordability of 436 housing units aimed at low-income...

Continue Reading
Essential Tips for New Dog Owners: Making Them Feel at Home

Updated Category News Views 232

Essential Tips for Welcoming a New Dog Bringing a new dog into your home can be an exhilarating experience filled with joys and challenges. This is especially true during peak pet adoption seasons like December and January when many families choose to add a furry member to their household. As a pet owner, providing a nurturing and stable environment is essential for your...

Continue Reading
Understanding New Fortress Energy's Recent Share Surge

Updated Category News Views 377

New Fortress Energy Celebrates Share Price Increase Recently, shares of New Fortress Energy Inc. (NASDAQ: NFE) experienced a remarkable after-hours jump of 20.54%, bringing the price up to $1.76. This impressive rise follows a strong performance during the regular trading session, where the stock concluded up 25.86% at $1.46. Details of the Credit Facility Amendment A...

Continue Reading
Koi Computers Celebrates Renewal of ISO 9001 Certification

Updated Category News Views 167

Koi Computers Celebrates ISO 9001:2015 Certification Renewal Koi Computers, a notable provider of high-performance computing (HPC) solutions to the government sector, has proudly renewed its ISO 9001:2015 certification. This achievement showcases the company’s unwavering commitment to quality management across all aspects of its operations, affirming its dedication to...

Continue Reading
Banijay Group's Recent Share Transactions Summary

Updated Category News Views 311

Overview of Share Transactions Banijay Group N.V. announced recent transactions concerning its shares as part of a broader strategy aligned with investor interests. These transactions occurred within the timeframe of early December and reflect ongoing activity in the company's stock management. Detailed Breakdown of Transactions From December 2 to December 6, Banijay...

Continue Reading